<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; BMY</title>
	<atom:link href="http://www.stockbloghub.com/tag/bmy/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(FRX) Forest Laboratories Earns Positive News on Pipeline</title>
		<link>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441</link>
		<comments>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441#comments</comments>
		<pubDate>Tue, 06 Mar 2012 21:31:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94441</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary endpoint in two phase III studies. The studies were conducted to evaluate cariprazine for the treatment of acute exacerbation of schizophrenia. Results showed that patients in the cariprazine arm achieved a significant improvement in symptom compared to patients in the placebo arm. Statistically significant separation from placebo was observed in all doses from week 2 and at each subsequent time point. Forest Labs and Gedeon said that the higher dose showed separation as early as week 1 of treatment.  The results were similar to data presented earlier from a phase IIb fixed-dose placebo-controlled study. Cariprazine is one of the candidates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806</link>
		<comments>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806#comments</comments>
		<pubDate>Sun, 19 Feb 2012 03:43:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[IPF]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[SPDR S&P International Financial Sector]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91806</guid>
		<description><![CDATA[We have maintained a Neutral rating on Gilead Sciences, Inc. (GILD) following appraisal of fourth quarter and full year 2011 results. Gilead’s adjusted earnings per share of 92 cents (including stock option expense) for the fourth quarter of 2011 missed the Zacks Consensus Estimate by 8 cents, as higher revenues were offset by increased research and development (R&#38;D) expenses. However, earnings were 2 cents above the year-earlier figure of 90 cents. Fourth quarter revenues were up 10% from the prior-year quarter to $2.2 billion, spurred by higher product sales. Total revenue also edged past the Zacks Consensus Estimate of $2.19 billion. Other than the fourth quarter miss, 2011 was an eventful year for Gilead on all fronts, namely commercial, regulatory and financial. Gilead’s strategy of creating fixed-dose combinations of existing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/18/gild-gilead-sciences-analyt-maintains-neutral-on-shares/91806/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug</title>
		<link>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536</link>
		<comments>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:54:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91536</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented from a phase III study that was conducted in patients with acute mania associated with bipolar I disorder. Results from the five-week multi-center, double-blind, placebo-controlled, parallel-group study showed that patients in the cariprazine arm experienced significant symptom improvement compared to patients in the placebo arm. The improvement was observed as early as the fifth day of treatment and at each subsequent time point studied. Cariprazine, a novel, orally active D2/D3 antagonist, was generally well tolerated. However, discontinuations due to adverse events were higher in the cariprazine arms compared to placebo. Forest Labs intends to analyze the data further. Results from this study were similar to those ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Earnings Season in Full Swing &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668</link>
		<comments>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668#comments</comments>
		<pubDate>Tue, 24 Jan 2012 17:21:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Colgate-Palmolive Company]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DeVry Inc.]]></category>
		<category><![CDATA[DV]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90668</guid>
		<description><![CDATA[Earnings Preview 1/20/12 Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&#38;P 500. By the end of the week we should have a very good handle on just how weak or strong this earnings season will be. The firms reporting next week read like a who’s who of American industry.  They.include: Abbott Labs (ABT), Apple (AAPL), Automatic Data Processing (ADP), AT&#38;T (T), Boeing  (BA), Bristol Myers (BMY), Caterpillar (CAT), CSX (CSX), Chevron (CVX), Colgate Palmolive (CL), Conoco Phillips (COP &#8211; Analyst Report) and DuPont (DD) – and that is just in the first four letters of the alphabet! It will also be a moderate week for economic data.  Things will be slow early in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/24/abt-earnings-season-in-full-swing-earnings-preview/90668/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ILMN) Two Major Biotech Trends In 2012</title>
		<link>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438</link>
		<comments>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438#comments</comments>
		<pubDate>Thu, 19 Jan 2012 23:34:54 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90438</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, January 18, 2012: Issue #1689 The workers at the restaurants and bars around Union Square in San Francisco have likely just about caught their breath. The 10,000 or so businesspeople who descended on the neighborhood for the J.P. Morgan Healthcare Conference drank their fill of Patron, ate a few tons of filets and guzzled thousands of gallons of Starbucks coffee. What makes the conference such a big deal is that it’s the largest and most important investor event of the year in the healthcare sector. There are other healthcare conferences put on by investment banks, but nothing comes close to the quality and number of companies and attendees at JPM. There were two important takeaways that emerged from the conference – themes ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/19/ilmn-two-major-biotech-trends-in-2012/90438/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DUK) 2012 Predictions for Income Investors</title>
		<link>http://www.stockbloghub.com/2012/01/09/duk-2012-predictions-for-income-investors/89336</link>
		<comments>http://www.stockbloghub.com/2012/01/09/duk-2012-predictions-for-income-investors/89336#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:57:11 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Electric Utilities]]></category>
		<category><![CDATA[Utilities]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[DUK]]></category>
		<category><![CDATA[Duke Energy Corporation]]></category>
		<category><![CDATA[Energy Transfer Partners L.P.]]></category>
		<category><![CDATA[Enterprise Products Partners Lp]]></category>
		<category><![CDATA[EPD]]></category>
		<category><![CDATA[ETP]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89336</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, December 28, 2011: Issue #1674 Last week, I reviewed my brilliant (and a few, let’s call them sub-brilliant) market calls for 2011. As the year winds down, here are my thoughts for what lies ahead in 2012 for income investors. Prediction #1: The “Crowded Trade” Chatter Heats Up Many Wall Street pros are scoffing at buying stocks with solid dividends. I believe this is for two reasons: The first is that in order for the Wall Street machine to make money, and that includes the financial media, you need to be trading constantly, generating commissions and hanging onto every word as to which stocks will go higher and which are going to tank. If you’re investing in dividend paying stocks, chances are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/duk-2012-predictions-for-income-investors/89336/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047</link>
		<comments>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:44:49 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89047</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Company News for January 04, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/08/bmy-company-news-for-january-04-2012-corporate-summary/89648</link>
		<comments>http://www.stockbloghub.com/2012/01/08/bmy-company-news-for-january-04-2012-corporate-summary/89648#comments</comments>
		<pubDate>Mon, 09 Jan 2012 04:48:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[China Petroleum & Chemical Corporation]]></category>
		<category><![CDATA[Devon Energy Corporation]]></category>
		<category><![CDATA[DVN]]></category>
		<category><![CDATA[Mead Johnson Nutrition Company]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MJN]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[SNP]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[United States Steel Corporation]]></category>
		<category><![CDATA[X]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89648</guid>
		<description><![CDATA[•    Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum Exploration &#38; Production, a unit of China Petroleum &#38; Chemical (NYSE:SNP) for $2.2 billion •    Pediatric nutrition company Mead Johnson Nutrition Co.’s (NYSE:MJN) shares advanced 3.81% to close at $71.35 after U.S. health officials confirmed they hadn’t found deadly bacteria in cans of the company&#8217;s Enfamil baby formula •    Shares of technology-licensing company Rambus Inc. (NASDAQ:RMBS) increased 7.42% to close at $8.11 after the company raised its forecast for the fourth quarter •    Steel producer U.S. Steel Corp.’s (NYSE:X) shares rose 6.46% after a better U.S. manufacturing activity report, striking a six-month high during the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/08/bmy-company-news-for-january-04-2012-corporate-summary/89648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Sees Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198</link>
		<comments>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198#comments</comments>
		<pubDate>Sat, 24 Dec 2011 15:13:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSC]]></category>
		<category><![CDATA[ELEMENTS BG Small Cap ETN]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89198</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a combination therapy in liver cancer patients who had either failed or were intolerant to Onyx Pharmaceuticals, Inc. / Bayer’s (ONXX/BAYRY) Nexavar. Results from the multicenter, double-blind, randomized study revealed that there was no improvement in the overall survival rate for patients treated with brivanib and the best supportive care (BSC) versus those in the placebo plus BSC arm. Bristol-Myers intends to present detailed data from the study at an upcoming scientific conference. The disappointing results of the BRISK-PS study notwithstanding, Bristol-Myers intends to continue evaluating the liver cancer candidate in three other late-stage studies. Bristol-Myers stated that it has conducted 29 studies till ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/24/bmy-bristol-myers-squibb-sees-pipeline-setback/89198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979</link>
		<comments>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979#comments</comments>
		<pubDate>Wed, 21 Dec 2011 17:42:14 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88979</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Drug Cleared by the European Commission</title>
		<link>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920</link>
		<comments>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920#comments</comments>
		<pubDate>Thu, 08 Dec 2011 19:01:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87920</guid>
		<description><![CDATA[AstraZeneca (AZN) and its partner Bristol-Myers Squibb (BMY) announced recently that Komboglyze has been approved by the European Commission (EC) in European Union (EU). Komboglyze is a combination of Onglyza (saxagliptin), a DPP-4 inhibitor and metformin, a generic drug for type II diabetes. AstraZeneca has co-developed Onglyza with Bristol-Myers. The EC cleared Komboglyze as an adjunct to diet and exercise to improve glycemic control in adults suffering from type II diabetes. Komboglyze is indicated for patients who show inadequate response to the maximum tolerated dose of metformin alone or those already being treated with the combination of Onglyza and metformin as separate tablets. Komboglyze is expected to provide single pill dosing convenience to patients currently taking Onglyza and metformin seperately. We remind investors that Komboglyze was approved by the US ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/azn-astrazeneca-drug-cleared-by-the-european-commission/87920/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Spotlight on Hepatitis-C Market</title>
		<link>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141</link>
		<comments>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88141</guid>
		<description><![CDATA[Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies &#8211; as evident by the deals being signed for the development of drugs for the treatment of HCV. We are talking about the recent announcements made by big players like Johnson &#38; Johnson (JNJ), Bristol-Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD). All three companies have made it clear they want a piece of the HCV market pie. Johnson &#38; Johnson’s Tibotec Pharmaceuticals and Bristol-Myers Squibb recently announced that they have decided to join forces for the development of Bristol-Myers’ daclatasvir (BMS-790052) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Earns FDA Approval</title>
		<link>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071</link>
		<comments>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071#comments</comments>
		<pubDate>Tue, 06 Dec 2011 00:54:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Warner Chilcott Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WCRX]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88071</guid>
		<description><![CDATA[Generic maker, Mylan Inc. (MYL) recently announced that its Indian subsidiary Mylan Laboratories has received tentative approval from the US Food &#38; Drug Administration (FDA) for a fixed-dose combination of generic versions of Bristol Myers Squibb’s (BMY) drug Reyataz and Abbott Labs&#8216; (ABT) Norvir for the treatment of HIV/AIDS. The fixed drug combination has been pre-qualified to be used in treatment of experienced patients by the World Health Organization (WHO). It can also be used in combination with other antiretroviral (ARV) agents and will be eligible for purchase in certain developing countries. The drug was approved through the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR). The drug will boost Mylan’s already strong portfolio of ARV’s in India. In a separate development, Mylan announced that Warner Chilcott Company (WCRX) filed a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/05/myl-mylan-earns-fda-approval/88071/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead&#8217;s Eviplera Drug is Cleared by European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725</link>
		<comments>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:44:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Questar Corporation]]></category>
		<category><![CDATA[STR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87725</guid>
		<description><![CDATA[Gilead Sciences, Inc (GILD), the world’s largest HIV drug maker, received marketing authorization from the European Medicines Agency (EMA) for the single tablet regimen (STR), Eviplera, for the treatment of HIV in previously untreated adults. The STR combines Gilead’s marketed HIV drug Truvada (a fixed-dose, once-daily tablet containing Gilead&#8217;s Viread and Emtriva) and Johnson and Johnson’s (JNJ) new HIV drug Edurant. The STR is already marketed as Complera in the US. The EMA however limited the use of Eviplera only in patients with low viral load (below 100,000 HIV RNA copies/mL). Complera/ Eviplera is the second STR approved in the EU for the treatment of HIV, the first being Atripla, which is marketed by Gilead and Bristol Myers Squibb (BMY). Gilead has a license and collaboration agreement with Tibotec Pharmaceuticals ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/gild-gileads-eviplera-drug-is-cleared-by-european-medicines-agency/87725/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Presents HCV Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567</link>
		<comments>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:50:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83567</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV). Bristol-Myers presented data from the mid-stage study at the 51st interscience conference on antimicrobial agents and chemotherapy held in the US. The double-blind study evaluated BMS-790052 at three doses (3 mg, 10 mg or 60 mg) in treatment-naïve patients infected with genotype 1 chronic HCV. Results from the study revealed that the rate of SVR24 (sustained virologic response – absence of detectable HCV at 24 weeks post treatment ) achieved by patients treated with a combination of BMS-790052, PEG-interferon alfa and ribavirin was higher across all evaluated doses than those receiving placebo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Brilinta Now in US</title>
		<link>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949</link>
		<comments>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:47:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81949</guid>
		<description><![CDATA[AstraZeneca plc (AZN) recently announced the US launch of Brilinta (ticagrelor). The drug was approved by the US Food and Drug Administration (FDA) last month, to reduce the rate of heart attack and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS). Following the launch, AstraZeneca plans to work with distribution partners and pharmacy customers to ensure that Brilinta is readily available for use. The regulatory body’s approval was based on the PLATO study, which compared Brilinta to clopidogrel in 18,624 patients suffering from ACS. The study demonstrated that there was no statistical difference in adverse reactions observed among patients treated with Brilinta, compared to those treated with clopidogrel. Clopidogrel, which is marketed worldwide by Bristol-Myers Squibb &#38; Co. (BMY) and Sanofi-Aventis (SNY) under the brand name Plavix, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/azn-astrazenecas-brilinta-now-in-us/81949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Get Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258</link>
		<comments>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258#comments</comments>
		<pubDate>Wed, 14 Sep 2011 16:41:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82258</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner Eliquis (apixaban) in patients suffering from erratic heartbeat and carrying at least one additional risk factor for stroke. The cardiac rhythm disorder is referred to as atrial fibrillation (AF). Bristol-Myers and Pfizer presented detailed data from the study at the European Society of Cardiology. Topline results were presented in June 2011. Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US. Data from the randomized, double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin in reducing the risk of stroke or systemic embolism. Patients treated with Eliquis were 21% less likely ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/14/bmy-bristol-myers-squibb-and-pfizer-get-encouraging-data/82258/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Drug Cleared in China</title>
		<link>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262</link>
		<comments>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262#comments</comments>
		<pubDate>Thu, 01 Sep 2011 17:26:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82262</guid>
		<description><![CDATA[Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first Iguratimod drug to hit the global market and will be used mainly to treat patients suffering from active RA. Iguratimod refers to a new disease-modifying, anti-rheumatoid therapy and belongs to the category of Disease Modifying Anti-rheumatic Drugs (DMARDs). The approval of Iremod by the Chinese regulatory authorities will not only boost Simcere’s top line but also widen the treatment options for patients suffering from the dreaded disease, whose incidence is on the rise. Iremod will operate in a highly lucrative market and will compete with players like Bristol-Myers (BMY), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALL) Company News for August 30, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/30/all-company-news-for-august-30-2011-corporate-summary/82281</link>
		<comments>http://www.stockbloghub.com/2011/08/30/all-company-news-for-august-30-2011-corporate-summary/82281#comments</comments>
		<pubDate>Tue, 30 Aug 2011 18:53:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[ALL]]></category>
		<category><![CDATA[Allstate Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[B]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Barnes Group Inc.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Crosshair Exploration & Mining Corporation]]></category>
		<category><![CDATA[CXZ]]></category>
		<category><![CDATA[JNY]]></category>
		<category><![CDATA[Jones Apparel Group Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Samson Oil & Gas Limited]]></category>
		<category><![CDATA[SSN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82281</guid>
		<description><![CDATA[•    Bank of America (NYSE:BAC) shares increased 8.12% to close at $8.39 after the bank disclosed it would be selling half of its holdings to China Construction Bank Corp in order to raise capital •    Share prices of insurer The Allstate Corp. (NYSE:ALL) advanced 8.50% to close at $26.30 after estimates showed property damage from Hurricane Irene was relatively lower •    Crosshair Exploration &#38; Mining (AMEX:CXZ) has told Australian American Mining Corp. Limited that it wishes to acquire its United States uranium assets. As per the proposal, AusAm will get US$12.85 million payable in Crosshair shares •    Share prices of Samson Oil &#38; Gas (AMEX:SSN) gained 3.83% after exploration company was awarded 956 net acres of leasehold land on conditional basis by the University of Wyoming •    Pharma giants Bristol-Myers ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/all-company-news-for-august-30-2011-corporate-summary/82281/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ONXX) Onyx Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354</link>
		<comments>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81354</guid>
		<description><![CDATA[We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved sales of the company’s only marketed drug, Nexavar (sorafenib) for cancer, which came in at $245.7 million (up 4% year-over-year) during the quarter, Onyx Pharma’s revenues experienced a 1.2% decline, amounting to $68.0 million. Earnings were further reduced as a result of higher-than-expected operating expenses. While research and development (R&#38;D) spend went up 16.2% to $50.3 million, selling, general and administrative (SG&#38;A) expenses shot up 43.6% to $38.2 million. Increased expenses for the development of carfilzomib led to higher R&#38;D spend and an increase in employee headcount and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Reports Solid Quarter</title>
		<link>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092</link>
		<comments>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:53:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80092</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) second quarter 2011 earnings (excluding special items) of $0.56 per share surpassed the Zacks Consensus Estimate by $0.01and the year-ago earnings by $0.02. Higher revenues boosted earnings in the reported quarter. On a reported basis (including special items), Bristol-Myers’ earnings in the quarter decreased 2% to $0.52 per share. The healthcare reform enacted in 2010 negatively impacted earnings in the reported quarter by $0.03. Net sales in the reported quarter climbed 14% to $5.4 billion. Foreign exchange positively impacted sales in the quarter by 4%. Revenues also surpassed the Zacks Consensus Estimate of $5.0 billion, driven by the impressive showing of Bristol-Myers’ lead drugs including blood thinner Plavix. US net sales in the quarter climbed 15% to $3.6 billion. Sales in international markets increased 13% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/bmy-bristol-myers-squibb-company-reports-solid-quarter/80092/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Gilead Sciences Earnings Grow With HIV Franchise</title>
		<link>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025</link>
		<comments>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025#comments</comments>
		<pubDate>Wed, 03 Aug 2011 19:46:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80025</guid>
		<description><![CDATA[Gilead Sciences Inc.’s (GILD) adjusted earnings per share of 95 cents for the second quarter of 2011 were 14 cents above the year-earlier earnings of 81 cents. The earnings growth was driven by a solid top-line performance in the reported quarter. Earnings were however a penny short of the Zacks Consensus Estimate. Second quarter revenues were up 11% from the prior-year quarter to $2.14 billion. Total revenues also topped the Zacks Consensus Estimate of $2.10 billion. Revenue performance was driven by a robust performance of the antiviral (HIV) and cardiovascular franchises. The Second Quarter in Detail Product sales, at $2.04 billion, were up 13% over the prior year due to a strong performance of antiviral products. Gilead’s product sales crossed the $2 billion mark for the first time in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/03/gild-gilead-sciences-earnings-grow-with-hiv-franchise/80025/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Gets HIV Rights from Gilead</title>
		<link>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031</link>
		<comments>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:42:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79031</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced that its Indian subsidiary Matrix Laboratories has been granted future rights to produce and sell generic versions of three investigational HIV therapies of Gilead Sciences, Inc. (GILD), if and when approved. The agreement aims to expand access to HIV therapies in developing nations. The therapies include elvitegravir, an integrase inhibitor; cobicistat, an antiretroviral (ARV) boosting agent; and the &#8220;Quad,&#8221; a once-daily combination pill of elvitegravir, cobicistat and Gilead’s another HIV combination medicine Truvada (Emtriva+Viread). The rights are an extension of the non-exclusive license granted to Matrix to produce and sell active pharmaceutical ingredients and finished products, including generic versions of Viread and Truvada in 95 developing countries including India. The license has now been expanded to include 16 additional countries, the three investigational medicines and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/myl-mylan-gets-hiv-rights-from-gilead/79031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229</link>
		<comments>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78229</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole).  Alkermes intends to present complete data from the study at an upcoming medical conference. The double-blind, randomized, placebo-controlled 20-week study evaluated the safety, tolerability and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in patients suffering from chronic, stable schizophrenia. Data from the study revealed that the candidate was generally well tolerated at all  doses and achieved therapeutically relevant plasma concentrations of Abilify. The pharmacokinetic profile backed the once-monthly dosing of ALKS 9070. Encouraged by the positive results, the company intends to commence a pivotal development program for the candidate by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Expands HIV Drug&#8217;s Reach</title>
		<link>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060</link>
		<comments>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060#comments</comments>
		<pubDate>Thu, 30 Jun 2011 20:41:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78060</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) inked a deal with Mylan Inc. (MYL) to expand the market for its HIV drug Reyataz (atazanavir sulfate). The deal allows Matrix to develop and sell the generic version of the HIV therapy in the Indian and sub-Saharan African markets. Apart from Reyataz, Mylan will also sell the generic versions of other Bristol-Myers HIV therapies such as Videx (didanosine) and Zerit (stavudine) in the above territories as per the agreement. The transaction marks the fifteenth deal signed by Bristol-Myers in the field of HIV and the fourth deal involving Reyataz. The deal also promises the pediatric versions of the HIV therapies. The deal permits Mylan’s Matrix Laboratories to secure prequalification from the World Health Organization (WHO) for all the offerings covered by the deal. This ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/bmy-bristol-myers-squibb-expands-hiv-drugs-reach/78060/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Drug Earns Positive Committee for Medicinal Products for Human Use Opinion</title>
		<link>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:07:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77581</guid>
		<description><![CDATA[Amgen (AMGN) recently announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for a label expansion for its oncology product, Vectibix. Amgen is looking to gain EU approval for the use of Vectibix in patients with wild-type KRAS metastatic colorectal cancer (mCRC) as a first-line treatment in combination with FOLFOX and second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). The CHMP had previously adopted a negative opinion regarding Amgen’s marketing authorization application for Vectibix’ label expansion. Amgen filed an appeal against the decision in March 2011 requesting the EMA to re-examine the CHMP’s opinion. With the CHMP now changing its view, a final decision from the European regulatory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amgn-amgen-drug-earns-positive-committee-for-medicinal-products-for-human-use-opinion/77581/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Presents Data on Two Studies</title>
		<link>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:34:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77782</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner AstraZeneca (AZN) presented encouraging data from two late-stage studies which evaluated their type II diabetes candidate dapagliflozin in conjunction with the extended-release version of metformin (XR). Data from the two 24-week studies, which evaluated adults suffering from type II diabetes, were presented at the American Diabetes Association (ADA) Scientific Sessions. Data from the studies revealed that there was a significant reduction in blood sugar levels in patients treated with dapagliflozin and metformin XR versus those treated with dapagliflozin or metformin XR alone and placebo. Moreover, no major events related to hypoglycemia were reported in the studies. Hypoglycemia refers to the situation of abnormally low levels of glucose in the blood. Results also revealed that patients treated with the combination of dapagliflozin and metformin ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bmy-bristol-myers-squibb-company-presents-data-on-two-studies/77782/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(API) Roche Holdings Partners with Evotec</title>
		<link>http://www.stockbloghub.com/2011/06/29/api-roche-holdings-partners-with-evotec/77707</link>
		<comments>http://www.stockbloghub.com/2011/06/29/api-roche-holdings-partners-with-evotec/77707#comments</comments>
		<pubDate>Wed, 29 Jun 2011 15:38:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Integrated Circuits]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77707</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently announced a collaboration with Evotec AG for the development of oncology drugs. Under the agreement, Evotec will use its PhosphoScout platform to discover protein-phosphorylations, which will help in predicting favorable dosage and efficacy of targeted cancer drugs in patients. Furthermore, Roche will conduct clinical trials and evaluate the development of companion diagnostics for the purpose of patient stratification. Initially, for three years, Roche and Evotec will conduct multiple biomarker studies for therapeutic antibodies or small molecule inhibitors. We note that this deal with Evotec is the third this month for Roche. In early June, Roche entered into a licensing agreement with TeaRx Ltd., wherein it granted TeaRx the development and commercialization rights to treatments for patients at risk of thrombosis in Russia and 12 other ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/api-roche-holdings-partners-with-evotec/77707/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb and Pfizer Report Positive Data on Blood Thinner Apixaban Drug</title>
		<link>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318</link>
		<comments>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:18:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77318</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) and partner Pfizer (PFE) announced encouraging top line data from a late-stage study (ARISTOTLE: n=18,201) which evaluated their blood thinner apixaban in patients suffering from an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation (AF). Apixaban will be marketed under the trade name Eliquis in the EU. The same trade name has been proposed in the US and other countries. Top-line results from the double-blind, multicenter study revealed that Eliquis was non-inferior to the standard therapy warfarin with respect to the combined outcome of stroke and systemic embolism. Data further revealed that Eliquis was superior to warfarin with respect to effectiveness and major bleeding. Bristol-Myers and Pfizer intend to seek approval from the US Food and Drug Administration (FDA) and also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/bmy-bristol-myers-squibb-and-pfizer-report-positive-data-on-blood-thinner-apixaban-drug/77318/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Gets Another Feather in its Cap</title>
		<link>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633</link>
		<comments>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633#comments</comments>
		<pubDate>Fri, 17 Jun 2011 14:42:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76633</guid>
		<description><![CDATA[Bristol-Myers Squibb Company’s (BMY) product portfolio was boosted further when the US Food and Drug Administration (FDA) approved its drug Nulojix (belatacept) to prevent the rejection of transplanted kidneys in adults. We remind investors that Bristol-Myers has succeeded in getting the drug approved in the US for the indication in its second attempt. In the second quarter of 2010, the FDA issued a complete response letter in response to biologic license application (BLA) submitted by the pharma major for Nulojix , asking for additional information. Subsequently, Bristol-Myers submitted it. In December 2010, the agency had thereby announced that it would review the re-submitted application by June 15, 2011 (action date). The agency cleared the drug following the review thereby delivering a further boost to the company. We note that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/17/bmy-bristol-myers-squibb-company-gets-another-feather-in-its-cap/76633/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Compan Gets Good News</title>
		<link>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752</link>
		<comments>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752#comments</comments>
		<pubDate>Wed, 15 Jun 2011 16:49:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74752</guid>
		<description><![CDATA[Bristol-Myers Squibb Company (BMY) received a boost when its blood-thinner Eliquis (apixaban) was cleared by the European Commission (EC) in 27 nations of the European Union (EU) for preventing venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery. The approval by the EC is the first approval for Eliquis, a new oral direct factor Xa inhibitor. Bristol-Myers has co-developed the drug with Pfizer (PFE). The approval was based on ADVANCE-2 and ADVANCE-3 studies which revealed that the drug was statistically superior to 40 mg once-daily Lovenox (enoxaparin) of Sanofi-Aventis (SNY) without increase in bleeding rates. The decision of the EC to approve Eliquis does not surprise us since the drug had won a positive recommendation from the Committee for Medicinal Products for Human Use ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/15/bmy-bristol-myers-squibb-compan-gets-good-news/74752/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AIG) Company News for May 12, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/12/aig-company-news-for-may-12-2011-corporate-summary/73928</link>
		<comments>http://www.stockbloghub.com/2011/05/12/aig-company-news-for-may-12-2011-corporate-summary/73928#comments</comments>
		<pubDate>Thu, 12 May 2011 15:10:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property & Casualty Insurance]]></category>
		<category><![CDATA[AIG]]></category>
		<category><![CDATA[American International Group Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Ener1 Inc.]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Harvest Natural Resources Inc]]></category>
		<category><![CDATA[HEV]]></category>
		<category><![CDATA[HNR]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Northwest Pipe Company]]></category>
		<category><![CDATA[NWPX]]></category>
		<category><![CDATA[Scientific Games Corporation]]></category>
		<category><![CDATA[SGMS]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73928</guid>
		<description><![CDATA[•    Shares of Ener1, Inc. (NASDAQ:HEV) plunged by 27.35%, after the company reported a large first-quarter net loss this week. Ener1 Inc. was also downgraded by Wunderlich Securities from &#8220;Hold&#8221; to &#8220;Sell&#8221; and its price target was reduced from $3.50 to $1.00 •    Global and federal government insurer American International Group, Inc (NYSE:AIG) revealed in a regulatory filing that they would sell 300 million shares to the public •    Strong earnings results that grew more than three times in the first quarter helped share prices of the pipeline maker Northwest Pipe Co (NASDAQ:NWPX) surge 6.40% to close at $24.45 •    Internet portal Yahoo! Inc (NASDAQ:YHOO) reported that Alibaba Group has transferred ownership of its online payments business to an entity controlled by the CEO of Alibaba. Reacting to the news, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/12/aig-company-news-for-may-12-2011-corporate-summary/73928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs First Quarter 2011 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667</link>
		<comments>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667#comments</comments>
		<pubDate>Mon, 18 Apr 2011 14:31:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71667</guid>
		<description><![CDATA[Abbott Laboratories (ABT) is all set to announce its first quarter 2011 results on April 20, 2011 before the opening bell. The Zacks Consensus Estimate for the first quarter of 2011 is $0.90, representing a year-over-year increase of 11.1%. Abbott Labs has surpassed earnings estimates consistently in the last four quarters with a trailing four-quarter average of 1.0%. Fourth Quarter 2010 Recap Abbott Laboratories reported fourth quarter earnings of $1.30 per share, a penny above the Zacks Consensus Estimate. Earnings increased 10.2% from the year-ago period. Higher revenues helped drive results. However, including one-time items, earnings declined 6.1% to $0.92 per share. Fourth quarter revenues increased 13.4% to $9.97 billion, above the Zacks Consensus Estimate of $9.89 billion. (Read our full coverage on the earnings report at Abbott Labs Tops ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/abt-abbott-labs-first-quarter-2011-earnings-preview/71667/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck&#8217;s Cancer Drug Earns US Food and Drug Administration Clearance</title>
		<link>http://www.stockbloghub.com/2011/04/13/mrk-mercks-cancer-drug-earns-us-food-and-drug-administration-clearance/71433</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mrk-mercks-cancer-drug-earns-us-food-and-drug-administration-clearance/71433#comments</comments>
		<pubDate>Thu, 14 Apr 2011 03:06:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71433</guid>
		<description><![CDATA[Recently, the US Food and Drug Administration (FDA) cleared Merck &#38; Co., Inc.’s (MRK) skin cancer (melanoma) drug, Sylatron (peginterferon alfa-2b). The once-weekly injectable drug has been approved by the US regulatory body for subcutaneous use. Sylatron has been approved as an additional therapy to treat skin cancer patients (with microscopic or gross nodal involvement) within 84 days of surgery including the removal of lymph nodes. The US agency has cleared Sylatron on the basis of data from the European Organisation for the Research and Treatment of Cancer (EORTC) study (n=1,256). The drug is prohibited for treating patients who are historically allergic to peginterferon alfa-2b or interferon alfa-2b. Moreover, the drug has not been cleared to treat skin-cancer patients suffering from autoimmune hepatitis and also those affected by hepatic decompensation. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mrk-mercks-cancer-drug-earns-us-food-and-drug-administration-clearance/71433/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Appeals EU Drug Opinion</title>
		<link>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440</link>
		<comments>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440#comments</comments>
		<pubDate>Mon, 04 Apr 2011 13:47:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70440</guid>
		<description><![CDATA[Amgen (AMGN) is appealing the negative recommendation issued by the Committee for Medicinal Products for Human Use (CHMP) for the use of Vectibix plus chemotherapy in patients with wild-type KRAS metastatic colorectal cancer (mCRC). The company has requested the European Medicines Agency (EMA) to re-examine CHMP’s opinion. Negative Opinion Issued in March 2011 The CHMP had adopted a negative opinion regarding Amgen’s marketing authorization application for Vectibix’s label expansion in March 2011. At that time, Amgen had said that it would appeal the opinion. Results from two studies (PRIME and ‘181) showed that Vectibix plus chemotherapy improved progression-free survival in patients with wild-type KRAS mCRC compared to only chemotherapy. Moreover, Amgen reported a higher response rate in the Vectibix arm compared to chemotherapy alone. Amgen is looking to drive Vectibix sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/04/amgn-amgen-appeals-eu-drug-opinion/70440/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Earns European Clearance for Baraclude</title>
		<link>http://www.stockbloghub.com/2011/03/16/bmy-bristol-myers-squibb-earns-european-clearance-for-baraclude/67935</link>
		<comments>http://www.stockbloghub.com/2011/03/16/bmy-bristol-myers-squibb-earns-european-clearance-for-baraclude/67935#comments</comments>
		<pubDate>Wed, 16 Mar 2011 16:11:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67935</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) received a boost with the European Commission (EC) approving Baraclude (entecavir) for an additional indication. The current approval by the European regulatory authorities allows Bristol-Myers to market Baraclude in 27 nations of the European Union for treating adults suffering from chronic hepatitis B (CHB) with decompensated liver disease. The US clearance for Baraclude for the same indication came in October 2010. Decompensated liver disease leads to improper functioning of the liver due to severe scarring of the organ and often needing liver transplantation. Approximately, 350 million people are infected by the CHB virus across the globe. The European approval for the additional indication was based on encouraging safety and efficacy data from a randomised, open-label, multi-centre study (ETV-048) study. Data from the study revealed that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/16/bmy-bristol-myers-squibb-earns-european-clearance-for-baraclude/67935/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Earnings Meet Expectations &#8211; Decrease From Year-Ago</title>
		<link>http://www.stockbloghub.com/2011/02/11/sny-sanofi-aventis-earnings-meet-expectations-decrease-from-year-ago/66751</link>
		<comments>http://www.stockbloghub.com/2011/02/11/sny-sanofi-aventis-earnings-meet-expectations-decrease-from-year-ago/66751#comments</comments>
		<pubDate>Fri, 11 Feb 2011 15:41:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Chicago Rivet & Machine Company]]></category>
		<category><![CDATA[CVR]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=66751</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) reported fourth quarter earnings of 96 cents per American Depository Share (ADS), a penny above the Zacks Consensus Estimate but below the year-ago earnings of $1.04. Full year earnings came in at $4.69 per ADS, in line with the Zacks Consensus Estimate and 1.7% above the year-ago earnings. Fourth quarter net sales declined 5.9%, with performance being impacted by the genericization of several products, especially Lovenox in the US, US healthcare reform and EU pricing austerity. Full year sales declined 0.8%. During 2010, sales worth more than €2 billion were impacted by generic competition. Meanwhile, EU austerity measures and the US healthcare reform impacted 2010 sales by €450 million. The Quarter in Detail Pharmaceutical segment sales declined 2.7% mainly due to the entry of generic Lovenox and Ambien ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/11/sny-sanofi-aventis-earnings-meet-expectations-decrease-from-year-ago/66751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMZN) Company News for January 28, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/01/29/amzn-company-news-for-january-28-2011-corporate-summary/65970</link>
		<comments>http://www.stockbloghub.com/2011/01/29/amzn-company-news-for-january-28-2011-corporate-summary/65970#comments</comments>
		<pubDate>Sat, 29 Jan 2011 22:48:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Catalog & Mail Order Houses]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[L-3 Communications Holdings Inc]]></category>
		<category><![CDATA[LLL]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Mead Johnson Nutrition Company]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MJN]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[POT]]></category>
		<category><![CDATA[Potash Corporation of Saskatchewan Inc]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[UA]]></category>
		<category><![CDATA[Under Armour Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65970</guid>
		<description><![CDATA[• Microsoft (NASDAQ:MSFT) reported Q2 EPS of $0.77, above the Zacks Consensus Estimate of $0.55 per share. Revenues for the quarter were $19.95 billion, well above the Zacks Consensus Estimate of $16.073 billion • Amazon.com (NASDAQ:AMZN) reported Q4 EPS of $0.91, ahead of the Zacks Consensus Estimate of $0.76 per share. Revenues for the quarter rose 36% year-over-year to $12.95 billion, above the Zacks Consensus Estimate of $9.281 billion • Under Armour (NYSE:UA) reported Q4 EPS of $0.44, well ahead of the Zacks Consensus Estimate of $0.21 per share. Revenues for the quarter rose 36% year-over-year to $301.2 million, above the Zacks Consensus Estimate of $284 million • L-3 Communications Holdings (NYSE:LLL) reported Q4 EPS of $2.37, ahead of the Zacks Consensus Estimate of $1.89 per share. Revenues for the quarter rose 1.1% year-over-year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/29/amzn-company-news-for-january-28-2011-corporate-summary/65970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Announces Response to FDA Complete Response Letter</title>
		<link>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664</link>
		<comments>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664#comments</comments>
		<pubDate>Tue, 25 Jan 2011 02:48:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65664</guid>
		<description><![CDATA[AstraZeneca (AZN) recently submitted a response to the Complete Response Letter (CRL) issued by the US Food and Drug Administration (FDA) for Brilinta (ticagrelor). In its response, the company has provided additional analyses of the Study of Platelet Inhibition and Patient Outcomes (PLATO) as requested by the FDA. AstraZeneca is looking to get Brilinta approved for the treatment of acute coronary syndrome (ACS). CRL Issued in Dec 2010 The FDA had issued a CRL on Dec 16, 2010 for Brilinta. At that time, the agency had asked AstraZeneca to conduct additional analyses of data from the PLATO trial. The trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). The company said that the additional ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/24/azn-astrazeneca-announces-response-to-fda-complete-response-letter/65664/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers Pipeline Setback for Motavizumab</title>
		<link>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405</link>
		<comments>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405#comments</comments>
		<pubDate>Wed, 22 Dec 2010 21:07:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63405</guid>
		<description><![CDATA[AstraZeneca (AZN) suffered another pipeline setback recently with the company announcing that it no longer intends to develop motavizumab for the prophylaxis of serious respiratory syncytial virus (RSV) disease. The company has requested the US Food and Drug Administration (FDA) to withdraw the Biological License Application (BLA) for the candidate. AstraZeneca expects to incur an impairment charge of $445 million in the fourth quarter of 2010 due to the discontinuation of the development of the candidate. The impairment charge, however, is not expected to impact the company’s core earnings. Rough Regulatory Path for Motavizumab AstraZeneca’s decision does not come as a major surprise as the regulatory process for motavizumab has been rocky. Earlier this year, the FDA’s Antiviral Drugs Advisory Committee had voted against the approval of motavizumab for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/22/azn-astrazeneca-suffers-pipeline-setback-for-motavizumab/63405/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Suffers FDA Regulatory Setback</title>
		<link>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756</link>
		<comments>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756#comments</comments>
		<pubDate>Sat, 18 Dec 2010 20:54:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=62756</guid>
		<description><![CDATA[AstraZeneca (AZN) recently suffered a major setback with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for Brilinta (ticagrelor). The company was seeking approval for the use of Brilinta in the treatment of acute coronary syndrome (ACS). The agency has asked AstraZeneca to conduct additional analyses of data from the Study of Platelet Inhibition and Patient Outcomes (PLATO). The PLATO trial was conducted to determine whether Brilinta was more effective in improving cardiovascular outcomes in ACS patients compared to Bristol-Myers Squibb Co./Sanofi-Aventis’ (BMY/SNY) Plavix (clopidogrel). Importantly, AstraZeneca has not been asked to conduct additional studies which could have delayed the approval process even further. The additional delay in Brilinta’s approval is a big disappointment for AstraZeneca which has been banking on Brilinta&#8217;s approval to help ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/18/azn-astrazeneca-suffers-fda-regulatory-setback/62756/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Bayer and Johnson &amp; Johnson Blood Thinner Xarelto Performs Well</title>
		<link>http://www.stockbloghub.com/2010/12/13/jnj-bayer-and-johnson-johnson-blood-thinner-xarelto-performs-well/59601</link>
		<comments>http://www.stockbloghub.com/2010/12/13/jnj-bayer-and-johnson-johnson-blood-thinner-xarelto-performs-well/59601#comments</comments>
		<pubDate>Mon, 13 Dec 2010 15:58:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59601</guid>
		<description><![CDATA[Germany’s Bayer (BAYRY) received a huge boost when its blood thinner Xarelto (rivaroxaban), co-developed with Johnson &#38; Johnson (JNJ), fared well in a pivotal, double-blind, late-stage study (n=14,264). Data from the study, presented at the annual meeting of the American Heart Association, revealed that treatment with Xarelto was more effective than warfarin (the current standard of care) for the prevention of stroke and embolism in patients with an erratic heartbeat. This cardiac rhythm disorder is referred to as atrial fibrillation. The randomized, double-blind study, known as ROCKET-AF (Rivaroxaban Once daily oral direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation), also revealed that treatment with Xarelto did not increase bleeding compared to the standard therapy. Bleeding is the major side-effect ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/13/jnj-bayer-and-johnson-johnson-blood-thinner-xarelto-performs-well/59601/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

